Drug Profile

ARQ 736

Alternative Names: ARQ-736

Latest Information Update: 20 Jan 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ArQule
Developer Merck & Co
Class Antineoplastics; Imidazoles; Oxazoles; Piperidines; Pyrazoles; Pyrimidines; Small molecules
Mechanism of Action Proto-oncogene protein b-raf inhibitors; Vascular endothelial growth factor A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Solid tumours

Most Recent Events

16 Jan 2020 ArQule has been acquired and merged into Merck & Co
31 Mar 2014 Discontinued - Phase-I for Solid tumours (late-stage disease) in Italy before March 2014 (Oral)
31 Mar 2014 Discontinued - Phase-I for Solid tumours (late-stage disease) in USA before March 2014 (Oral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com